The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...
The evolving treatment landscape in polycythemia vera (PV) is shifting from a focus on hematocrit control to a more ...
To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...
Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ...
Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results